Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive News
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?Authored by Leo Miller. Originally Published: 4/6/2026. 
Key Points
- Top companies across the nuclear, pharmaceutical, and travel industries just made significant buyback announcements.
- However, one of these announcements signals less confidence than initially meets the eye.
- While shares of a nuclear behemoth take a hit, a $5 billion buyback authorization and analyst price targets support its outlook.
- Special Report: Elon Musk already made me a “wealthy man”
Some of the world’s biggest stocks across nuclear, pharma, and travel are looking to support their shares through buybacks. Not all buyback announcements are equal, though. By examining a company’s historical repurchase activity, investors can better gauge management’s confidence. Two recent announcements stand out as positive signals; a third is more questionable. Constellation’s Buybacks to Pick up Big-TimeDespite a strong 52-week return of 59%, nuclear giant Constellation Energy (NASDAQ: CEG) has struggled in 2026. Shares are down more than 20% year to date amid several headwinds, including guidance that missed expectations. At the midpoint of its 2026 forecast, the company projects adjusted earnings per share of $11.50 versus analysts’ estimates of $11.72, according to reporting and the company’s guidance release.
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776.
One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. Read Porter Stansberry's full breakdown and protect your wealth now
PJM Interconnection, which operates the grid across 13 Eastern states, has implemented price caps through 2028 in response to soaring electricity rates. Because Constellation has significant exposure in PJM territory, those caps could constrain revenue upside; regulators are considering proposals to extend the caps beyond 2028. Still, Constellation is signaling confidence by authorizing a $5 billion share buyback plan, roughly 5% of its about $100 billion market capitalization. Management also expects to use that capacity relatively quickly, targeting exhaustion by the end of 2027. If Constellation meets that timeline, it would represent a dramatic acceleration in repurchases: the firm spent only about $400 million on buybacks in 2025 and peaked at roughly $1 billion annually in 2023 and 2024. The faster pace suggests management currently sees value in the stock. Are Novo’s Buyback Plans a Sign of Strength or Weakness?Weight-loss and diabetes drugmaker Novo Nordisk A/S (NYSE: NVO) has suffered a steep decline. Shares are down about 40% over the past 52 weeks and more than 20% in 2026; from their March 2024 peak they have fallen nearly 75%. The main driver is waning market share for its flagship drugs Ozempic and Wegovy. Eli Lilly and Company (NYSE: LLY) has introduced competing drugs that appear more effective in many patients, boosting Lilly’s sales while pressuring Novo. Still, Novo continues to compete on oral GLP-1 formulations and potential next-generation injectables, where it has shown solid efficacy versus Lilly. Neither company yet has a next-gen injectable approved, which leaves room for future shifts in market share. Recently, Novo initiated a share repurchase program of 15 billion Danish kroner (about $1.54 billion) and plans to execute it over roughly 10 months, according to reports. That amount is modest—just under 1% of the company’s roughly $165 billion market capitalization. The program would materially accelerate repurchases versus 2025’s roughly $218 million of buybacks. Even so, it would remain small relative to Novo’s historical activity; 2026 would rank among the company’s lowest buyback years since 2010. Given the dramatic decline in Novo’s share price, that relatively muted buyback program raises questions about management’s confidence. Carnival: Sales, Fuel Costs, and Buybacks Are on the RiseCruise operator Carnival (NYSE: CCL) has given back much of the 23% total return it generated in 2025 and is down about 15% in 2026. Volatility this year has been driven largely by the conflict in Iran and higher oil prices, which push up the company’s fuel costs. Demand for cruises, however, remains strong. Carnival reported record Q1 revenue and operating income, and customers have already booked roughly 85% of cabin capacity for 2026 at historically high prices. The company also noted record cumulative future-year bookings in Q1, giving management significant visibility into future sales. To reinforce that confidence, Carnival authorized a $2.5 billion buyback program—about 7% of its roughly $36 billion market capitalization. The firm did not repurchase shares in 2025, so this program could mark a substantial step up in buyback activity. Carnival also plans to return $14 billion to shareholders by 2029 through a combination of buybacks and dividends; the stock currently carries an indicated yield of 2.3%. Despite Outlook Disappointment, Analysts Remain Bullish on CEGRelatively speaking, Constellation and Carnival’s buyback announcements convey more confidence than Novo’s. Constellation is especially interesting: despite the recent pullback, its central role in nuclear energy underpins the longer-term outlook. Analysts remain optimistic. The MarketBeat consensus price target sits near $387, implying roughly 40% upside. Targets revised after the company’s guidance update average about $351, which still suggests more than 25% upside. |
Post a Comment
Post a Comment